CTNNB1 and cancer: Still, the HRs of CTRT versus RT for NSMP cancers were similar to those observed in the PORTEC-3 trial.8 The lack of significant effect of CTRT may be due to the relatively small numbers and molecular heterogeneity that characterizes NSMP EC.1 Additional studies directed at refinement of NSMP EC, such as characterization of CTNNB1 exon-3 mutations, the potential fifth molecular subgroup,3,32 may elucidate which patients with NSMP EC might benefit from intensified adjuvant treatment.